Key market opportunities for Lucentis include its broad approval for multiple retinal diseases, its proven clinical efficacy, and strong physician trust. Despite competition, its established global ...
Biogen has gained rights to market two potential ophthalmology biosimilars in major markets including the US, Europe and Japan, under a new agreement signed with Samsung Bioepis. Samsung Bioepis is a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results